Received Jun 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | — | IM / UN |
Patient received a dose of the Heplisav-B vaccine, when the vaccine is indicated for ages 18 years and older. The patient was 18 months at the time of the incident.
N/A
N/A
N/A
No known allergies